Ubs Asset Management Americas Inc Travere Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 163,175 shares of TVTX stock, worth $3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
163,175
Previous 178,749
8.71%
Holding current value
$3 Million
Previous $1.47 Million
55.34%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TVTX
# of Institutions
193Shares Held
83.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$140 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$140 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$127 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$86.1 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$79.7 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.18B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...